Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02 2024 - 8:00AM
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical
company focused on the development and commercialization of
therapeutics for central nervous system (CNS) disorders, today
announced that Sharon Mates, Ph.D., Chief Executive Officer and
Chairman, is scheduled to present at the 42nd Annual J.P. Morgan
Healthcare Conference on Tuesday, January 9, 2024 at 8:15 a.m. PT
in San Francisco, CA.
The live and archived webcast can be accessed under "Events
& Presentations" in the Investor Relations section of the
Company's website at www.intracellulartherapies.com. Please log in
approximately 5-10 minutes prior to the event to register and to
download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded
on Nobel prize-winning research that allows us to understand how
therapies affect the inner-workings of cells in the body. The
company leverages this intracellular approach to develop innovative
treatments for people living with complex psychiatric and
neurologic diseases. For more information, please visit
www.intracellulartherapies.com.
Contact:
Intra-Cellular Therapies, Inc.Juan Sanchez, M.D. Vice President,
Corporate Communications and Investor Relations646-440-9333
Burns McClellan, Inc.Cameron
Radinoviccradinovic@burnsmc.com212-213-0006
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Apr 2024 to May 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From May 2023 to May 2024